Pharmacists in Barceloneta, PR Accepting Medicare

26 Pharmacists found. Showing 21 - 26

Edith Marie Rodriguez-alicea, PHARMD. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2 Carr 140, Barceloneta, PR 00617 Phone: 787-846-6829

Yamirelis Ramirez Santiago, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2 Carr 140, Barceloneta, PR 00617 Phone: 787-846-6829

Felix Ali Maldonado, R.PH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 9 Calle Georgetti, Barceloneta, PR 00617 Phone: 787-846-3474    Fax: 787-846-0219

Brenda L. Torres, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: Carr 140 Km 67 5, Bo Llana Anadas, Barceloneta, PR 00617 Phone: 787-505-4756    Fax: 787-970-0839

Luz Nogueras-santiago Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 116 Ave Los Rosales, Parcelas Imbery, Barceloneta, PR 00617 Phone: 787-510-0148

Arleen A Vazquez, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2 Carr 140, Barceloneta, PR 00617 Phone: 787-846-4104    Fax: 787-846-7351

News Archive

St. Jude discovers factors that accelerate resistance to Gleevec targeted therapy in lymphoblastic leukemia

Results of a study by investigators at St. Jude Children's Research Hospital provide strong evidence for why the drug imatinib (Gleevec), which has revolutionized the treatment of chronic myelogenous leukemia (CML), is often unable to prevent relapse of a particularly aggressive form of acute lymphoblastic leukemia (ALL).

Stereotypical imperfections offer health benefits when it comes to bodies

Having an imperfect body may come with some substantial benefits for some women, according to a new article in the December issue of Current Anthropology.

Study shows those with weak immune systems should avoid the shower

A study out of the San Diego State University Center for Microbial Sciences reveals that hundreds of millions of colorful bacteria thrive on shower curtains, waiting to attack those who think they are getting clean.

Amgen announces results from pivotal Phase 3 "408" trial of Vectibix

Amgen today announced detailed results from a new biomarker analysis of the pivotal Phase 3 "408" trial of Vectibix® (panitumumab) plus best supportive care compared to BSC alone. The analysis used massively parallel, next-generation sequencing technology to investigate whether mutations in nine genes known to be mutated in colorectal cancer, including the previously unanalyzed exon 3 mutation of the KRAS gene, are predictive of response to Vectibix in metastatic colorectal cancer.

Read more Medical News

› Verified 3 days ago

• 1
• 2(current)